Heart failure can get worse over time. If not managed and treated, it can lead to poor quality of life, hospitalizations and death. Heart failure causes more than 377,000 deaths each year in the United States.2
In its early stages, heart failure can often be managed with medicines and healthy lifestyle changes. As heart failure gets worse and the heart becomes weaker, medicine may no longer work as well. Other treatments, such as implantable devices that help your heart pump blood, may be an option.3
Doctors use the New York Heart Association (NYHA) classes of heart failure to define the seriousness of a person’s heart failure. As heart failure symptoms get worse and it gets harder to do physical activities, the heart failure class level changes from early-stage heart failure (Class I and II) to advanced heart failure (Class III and IV).
The HeartMate 3 LVAD is a proven, well-known choice for people with advanced heart failure (NYHA Class IIIB-IV). It's a small device that is connected to your heart to help it pump oxygen-rich blood throughout your body.
In a large clinical study, people with advanced heart failure implanted with the HeartMate 3 LVAD have been shown to have less heart failure symptoms, enjoy a much improved quality of live and live longer.4
Over 20,000 people have been implanted with a HeartMate 3 LVAD device worldwide.5
Associated risk of LVAD therapy can include bleeding, stroke, thrombosis and other possible adverse events.
If your doctor thinks advanced options may be necessary, including LVAD therapy, you will be referred to an advanced heart failure specialist for evaluation and for more information. The earlier you are seen by a heart failure specialist before your condition becomes worse, the more time you will have to decide and plan for your treatment.
Learn more about Heartmate LVAD Therapy
These materials are not intended to replace your doctor’s advice or information. For any questions or concerns you may have regarding the medical procedures, devices and/or your personal health, please discuss these with your physician.
The above testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.
Rx Only
Brief Summary: Prior to using these devices, please review the Instructions For Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
HeartMate 3™ LVAS Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area.
HeartMate 3 Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.
HeartMate 3 Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System include, but are not limited to those listed below: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS), thromboembolism, pericardial fluid collection, pump pocket or pseudo pump pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) and pump thrombosis.
MAT-2105716 v4.0